Status:

NOT_YET_RECRUITING

Prospective Validation of a Pharmacological Biomarker for Low-Dose Rituximab in Rheumatoid Arthritis

Lead Sponsor:

University Hospital, Tours

Conditions:

Rheumatoid Arthritis (RA)

Eligibility:

All Genders

18+ years

Brief Summary

Evaluation of the prediction of clinical response to rituximab at a dose of 1000 mg once using a pharmacological model including several pharmacokinetic and pharmacodynamic parameters.

Detailed Description

Rituximab is an anti-CD20 monoclonal antibody which is effective in RA. The dose indicated in the marketing authorisation is 1000 mg twice per cycle. However, rituximab is associated with adverse even...

Eligibility Criteria

Inclusion

  • . Age ≥ 18 years
  • Diagnosis of rheumatoid arthritis meeting ACR/EULAR 2010 criteria.
  • Candidates for a Low Dose regimen: on standard dose rituximab and with a good clinical response according to the referring rheumatologist. No maximum duration of use of standard-dose rituximab has been defined.
  • In the case of co-prescription of csDMARDs (Methotrexate, Leflunomide, Salazopyrine, Plaquenil), the dose must have been stable for 3 months.
  • If corticosteroids are co-prescribed, the dose should be ≤ 10 mg/d and stable for 3 months.

Exclusion

  • Other associated targeted disease-modifying therapy
  • Sjögren's syndrome or other associated inflammatory rheumatism
  • Fibromyalgia or other pathology having an impact on the assessment of disease activity
  • Any active haematological disease affecting lymphocytes (chronic lymphocytic leukaemia, Hodgkin's and non-Hodgkin's lymphomas, lymphoplasmacytic lymphoma, T lymphoma).
  • Opposition to data processing
  • No inclusion of persons covered by articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the Public Health Code (e.g. minors, protected adults, etc.).

Key Trial Info

Start Date :

September 1 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

April 1 2028

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT06933134

Start Date

September 1 2025

End Date

April 1 2028

Last Update

August 7 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University hospital

Tours, France, 37044

Prospective Validation of a Pharmacological Biomarker for Low-Dose Rituximab in Rheumatoid Arthritis | DecenTrialz